Sector News

Sobi names former Shire exec to head North American business

May 1, 2019
Life sciences

Swedish Orphan Biovitrum, the Nordic biotech company known as Sobi, has appointed Amy Pott as the new head of Sobi North America. She takes over effective today, replacing Rami Levin who is leaving Sobi.

“Sobi North America is entering a new phase in line with Sobi’s growth strategy, with the workforce growing more than fourfold in just more than a year. The launch of Gamifant [emapalumab] and the integration of Synagis are key to the company’s future and I am delighted to welcome Amy to Sobi for her to take on this challenge,” says Guido Oelkers, chief executive.

Ms Pott was most recently group vice president and US franchise head for Internal Medicine & Oncology at Shire, which has recently been acquired by Japan’s Takeda. She was also group VP for US Commercial Operations at Shire and VP of strategy, planning and analytics at Baxalta, all roles based in Boston. Prior to her roles in the USA, Ms Pott spent 10 years at Baxter, where she held UK and international roles working with both rare diseases and medical devices. During her time in the UK she built up Baxter’s UK & Ireland market access team.

Ms Pott has a strong background in private and public healthcare, having worked as an Associate for APCO Worldwide in London, Sacramento and San Francisco supporting a wide range of public sector companies. Previous to her roles at Baxter and Shire, Pott held positions at the National Institute for Health and Clinical Excellence (NICE) and the NHS Confederation. Amy Pott will be part of the Sobi executive committee.

Source: The Pharma Letter

comments closed

Related News

September 26, 2021

Lonza invests to expand drug product development and manufacturing services in Switzerland

Life sciences

Lonza will invest to expand its drug product manufacturing network in Switzerland. The investment will include installation of a new aseptic fill and finish line in Stein and the expansion of Drug Product Services in Basel. The expansion adds new capabilities to support clinical and commercial manufacturing and enhances existing drug product service offering in Basel and Visp.

September 26, 2021

Repairing heart damage by transiently turning back the clock

Life sciences

Partial reprogramming of adult heart cells to a fetal-like state could help repair heart damage following cardiac injury or disease, scientists at the Max Planck Institute for Heart and Lung Research showed in mice. 

September 26, 2021

Merck women’s health spinoff Organon debuts first awareness campaign, taking on unplanned pregnancy

Life sciences

When Merck’s women’s health spinoff Organon launched in June, it promised to listen to—and amplify—women’s voices on overlooked health concerns. Now, the company is getting specific. Organon hopes to ignite a conversation about an issue that affects 121 million women around the world every year.

Send this to a friend